Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Communication Bridge: Optimizing an Evidence-based Intervention for Individuals With Primary Progressive Aphasia
Authors not listed
University of Chicago · 2024
Abstract
This study will use a randomized controlled trial design to evaluate the effect of two evidence-based treatments for adults with mild-moderate Primary Progressive Aphasia (PPA). The aim of the study is to help us better understand the effects of speech-language therapy on communication abilities in individuals with PPA.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-15 MST
Cite this
APA
Anonymous. (2024). Communication Bridge: Optimizing an Evidence-based Intervention for Individuals With Primary Progressive Aphasia. <em>University of Chicago</em>. https://clinicaltrials.gov/study/NCT06191198
Vancouver
Anonymous. Communication Bridge: Optimizing an Evidence-based Intervention for Individuals With Primary Progressive Aphasia. University of Chicago. 2024.
BibTeX
@misc{anon2024Commun,
title = {Communication Bridge: Optimizing an Evidence-based Intervention for Individuals With Primary Progressive Aphasia},
author = {Anonymous},
journal = {University of Chicago},
year = {2024},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
CanSino Biologics Inc. 2020
Open access · US-GOV
A Randomized, Observer-Blind, Dose-escalation Phase I/II Clinical Trial of Ad5-nCoV Vaccine in Healthy Adults From 18 to <85 Years of Age in Canada
Vanderbilt University Medical Center 2025
Open access · US-GOV
Prevalence and Care Partner Burden of Individuals With Alzheimer's Disease
Vanderbilt University Medical Center 2024
Open access · US-GOV
Prevalence and Detection of Voice and Swallowing Disorders in Adults With and Without Alzheimer's Disease
Indiana University 2010
Open access · US-GOV
Alzheimer's Disease Multiple Intervention Trial
SK Chemicals Co., Ltd. 2013
Open access · US-GOV
A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess the Immunogenicity and Safety of 'NBP607(Trivalent Inactivated Cell Culture-derived Influenza Vaccine)' in Healthy Children and Adolescents Aged 6 Month ~ 18 Years)
Nature Reviews Disease Primers 2022
Preprint · OA